Markets

Pre-market Movers In Healthcare Sector: MTP, FLDM, RDHL, ENLV, TRIB, RWLK...

(RTTNews) - What's moving these stocks in the pre-market hours today?

In the Green

1. Midatech Pharma plc (MTP) is up over 46% at $2.94 in pre-market trading Monday, following encouraging headline results from a Phase I study of MTX110 in patients with Diffuse Intrinsic Pontine Glioma. The primary endpoint of the study was to determine the dosage regimen to be used in a proposed Phase II study. The phase I study, conducted at the University of California, San Francisco, supports a dose of between 60µM and 90µM of MTX110.

2. Fluidigm Corporation (FLDM) is up more than 19% at $8.06 in pre-market hours on no news. The company is slated to report third-quarter 2020 financial results on Thursday, November 5, 2020, after the close of the market. Early this month, the company announced a program to expand the availability of Fluidigm COVID-19 tests for U.S. colleges and universities. The Fluidigm COVID-19 test is a non-invasive, saliva-based test for the SARS-CoV-2 virus and will be provided to qualifying institutions at a cost as low as $5 per test.

3. RedHill Biopharma Ltd. (RDHL), a commercial-stage specialty biopharmaceutical company, is up over 12% at $11.38 in pre-market trading Monday. A phase 2/3 clinical study evaluating Opaganib in patients hospitalized with severe SARS-COV-2 infection and pneumonia, and a phase II study of Opaganib in patients with severe COVID-19 are ongoing.

4. Enlivex Therapeutics Ltd. (ENLV) is up 9% at $14.38 in pre-market hours Monday. On October 13, the Israeli Ministry of Health authorized the initiation of a proposed investigator-initiated Phase II clinical trial of the company's drug candidate Allocetra in severe and critical COVID-19 patients. In a phase Ib trial that included five COVID-19 patients, three in severe condition and two in critical condition, the results of which were reported recently, all five patients completely recovered from their respective severe/critical condition and were released from the hospital after an average of 5 days (severe) and 9 days (critical), following administration of Allocetra.

5. Entasis Therapeutics Holdings Inc. (ETTX) is up over 9% at $2.26 in pre-market trading. A phase III registration trial of SUL-DUR for the treatment of patients with pneumonia and bloodstream infections caused by carbapenem-resistant Acinetobacter baumannii, dubbed ATTACK, and a phase III registration trial of Zoliflodacin for the treatment of uncomplicated gonorrhea are underway. As of June 30, 2020, cash, cash equivalents and short-term investments were $50.8 million.

6. ADMA Biologics Inc. (ADMA) is up over 7% at $2.44 in pre-market hours today on no news. Last month, the company launched COVID-19 ImmunoRank Neutralization MICRO-ELISA, a proprietary, fully-validated ELISA assay for the detection of SARS-CoV-2 neutralizing antibodies in plasma. The company is expected to report Q3 financial results in the first week of November.

7. ADiTx Therapeutics Inc. (ADTX) is up over 9% at $2.40 in pre-market trading Monday, adding to Friday's gain of over 13%. Last month, the company signed a collaboration agreement with Salveo Diagnostics Inc. to commercialize the AditxtScore Platform starting this quarter. AditxtScore for COVID-19 is designed for use in detecting antibodies against SARS-CoV-2 antigens. The application seeking Emergency Use Authorization for AditxtScore was submitted to the FDA on Aug.24.

8. Trinity Biotech plc (TRIB) is up over 5% at $2.90 in pre-market trading today. The company is slated to report third-quarter financial results today.

In the Red

1. ReWalk Robotics Ltd. (RWLK) is down more than 9% at $1.29 in pre-market hours Monday, giving back some of what it gained on Friday. The stock had jumped over 23% to $1.43 on Friday. The company is slated to report Q3 financial results on November 11. On average, Wall Street analysts expect the company to incur a loss of $0.16 per share on revenue of $1.1 million.

2. Catabasis Pharmaceuticals, Inc. (CATB) is down over 8% at $5.75 in pre-market hours on no news. The company's lead candidate is Edasalonexent, under a phase III trial in Duchenne muscular dystrophy, dubbed PolarisDMD, with topline results expected this quarter.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Latest Markets Videos

RTTNews

Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.

Learn More